|
MechanismM3 receptor antagonists [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
在一线化疗失败的晚期非小细胞肺癌患者中,评价BIBF 1120或安慰剂联合多西他赛治疗的有效性和安全性
[Translation] To evaluate the efficacy and safety of BIBF 1120 or placebo in combination with docetaxel in patients with advanced non-small cell lung cancer who failed first-line chemotherapy
在接受一线化疗失败后的IIIB/IV期或复发性非小细胞肺癌患者中,比较接受BIBF 1120加标准多西他赛治疗与安慰剂加标准多西他赛治疗的有效性和安全性,生活质量和BIBF1120药代动力学的数据也将进行分析。
[Translation] To compare the efficacy and safety of BIBF 1120 plus standard docetaxel versus placebo plus standard docetaxel in patients with stage IIIB/IV or recurrent non-small cell lung cancer after failure of first-line chemotherapy, Life Data on the quality and pharmacokinetics of BIBF1120 will also be analyzed.
100 Clinical Results associated with Melep (Beijing) Pharmaceutical Research Co Ltd
0 Patents (Medical) associated with Melep (Beijing) Pharmaceutical Research Co Ltd
100 Deals associated with Melep (Beijing) Pharmaceutical Research Co Ltd
100 Translational Medicine associated with Melep (Beijing) Pharmaceutical Research Co Ltd